Contents
18 September 2019
Vol 11, Issue 510
Vol 11, Issue 510
Research Articles
- Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa
In South Africans, the RV144 HIV vaccine regimen elicited robust immune responses that have been associated with vaccine efficacy.
- Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Combined targeting of KRAS-G12C, mTOR, and IGF1R enhances and extends the response to recently developed KRAS-G12C inhibitors in lung cancer models.
- Yin Yang 1 protein ameliorates diabetic nephropathy pathology through transcriptional repression of TGFβ1
YY1 transcriptionally represses TGFB1 in mice and may be a potential drug target for treating diabetic nephropathy.
- Adipose tissue–derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases
Adipose-secreted WNT5A triggers vascular disease in obesity, activating vascular smooth muscle cell migration by an NADPH oxidase–dependent mechanism.
- Antimalarial pantothenamide metabolites target acetyl–coenzyme A biosynthesis in Plasmodium falciparum
Pantothenamides form antimetabolites that interfere with acetyl-CoA metabolism in the human malaria parasite Plasmodium falciparum.
Editors' Choice
- You (don’t) give me fever
A baseline transcriptional signature in peripheral blood is associated with protection from febrile malaria in children.
- PD-L2 in follicular lymphoma: Sidekick or star?
Immune profiling of follicular lymphoma reveals a role for PD-L2 expression in predicting early progression and survival.
- Interception! A decoy scaffold disrupts autoimmunity
Subcutaneous implantation of microporous collagen scaffolds decorated with a model autoantigen prevents onset of autoimmune encephalomyelitis in mice.
Erratum
About The Cover
ONLINE COVER HIV Vaccine on Trial. Polyfunctional HIV-specific T cells, depicted in this heatmap, contribute to protective immunity generated by vaccination. Gray et al. designed the HVTN 097 HIV vaccine trial in South Africa to test the RV144 regimen used in Thailand, which is the only HIV vaccine that has shown some efficacy. Although the HIV strains circulating in South Africa differ from those used to make the vaccine, strong immune responses associated with protection were observed. The vaccine seemed more immunogenic in the South African participants, suggesting that the RV144 HIV vaccine regimen could be used to prevent infection in areas where HIV is endemic. [CREDIT: GRAY ET AL./SCIENCE TRANSLATIONAL MEDICINE]
